% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Karneboge:276318,
      author       = {Karneboge, Jonas and Haberstroh, Julia and Geschke,
                      Katharina and Perry, Julia and Radenbach, Katrin and Jessen,
                      Frank and Rostamzadeh, Ayda},
      title        = {{F}acing the new diagnostic and treatment options of
                      {A}lzheimer's disease: {T}he necessity of informed consent.},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {1},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-00281},
      pages        = {e14204},
      year         = {2025},
      abstract     = {With advances in biomarker-based detection of Alzheimer's
                      disease (AD) and new treatment options with
                      disease-modifying treatments (DMTs), we are heading toward a
                      new conceptualization of diagnostics and therapy in the
                      early stages of AD. Yet consensus guidelines on best
                      clinical practices in predictive AD diagnostics are still
                      developing. Currently, there is a knowledge gap regarding
                      counseling and disclosure practices in early symptomatic
                      disease stages, its implications for dementia risk
                      estimation, and DMTs with associated risks and benefits. The
                      crucial feature is the capacity of patients with (mild)
                      cognitive impairment, eligible for DMTs, to consent. This
                      perspective aims to (1) discuss the current challenges in
                      assessing capacity to consent and (2) highlight the
                      importance of a supported (informed) decision-making
                      process. Measures to facilitate informed decision-making of
                      patients constitute an ethical approach to enhancing the
                      quality of care in this evolving therapeutic landscape.
                      HIGHLIGHTS: This perspective: Explores biomarker-based early
                      symptomatic AD detection and the implications for patient
                      care. Emphasizes supported decision-making in DMTs for MCI
                      and dementia patients. Discusses the need for standardized
                      tools to assess the capacity to consent. Aligns diagnostic
                      and treatment approaches with ethical care standards.
                      Enhances patient autonomy in the evolving AD therapeutic
                      landscape.},
      keywords     = {Humans / Alzheimer Disease: diagnosis / Alzheimer Disease:
                      therapy / Alzheimer Disease: drug therapy / Informed Consent
                      / Biomarkers / Cognitive Dysfunction: diagnosis / Cognitive
                      Dysfunction: therapy / Decision Making / Mental Competency /
                      anti‐amyloid therapy (Other) / biomarkers (Other) /
                      capacity to consent (Other) / communication (Other) /
                      dementia risk estimation (Other) / early diagnosis (Other) /
                      informed consent (Other) / supported decision‐making
                      (Other) / Biomarkers (NLM Chemicals)},
      cin          = {AG Jessen},
      ddc          = {610},
      cid          = {I:(DE-2719)1011102},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39740107},
      pmc          = {pmc:PMC11772727},
      doi          = {10.1002/alz.14204},
      url          = {https://pub.dzne.de/record/276318},
}